EARNINGS PER SHARE

3 Months Ended

Mar. 31, 2026

Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of shares of the Company’s common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of the Company’s common stock outstanding adjusted for the effect of dilutive common stock equivalents.

The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):


	Three months ended March 31,
	2026		2025

Numerator:
Net loss	$	(2,122)	$	(772)

Denominator:
Weighted average shares of common stock outstanding	11,006		10,948
Effect of dilutive common stock equivalents	—		—
Weighted average shares of common stock outstanding	11,006		10,948

Loss per share - basic	$	(0.19)	$	(0.07)

Loss per share - diluted	$	(0.19)	$	(0.07)

The Company was in a loss position for the three months ended March 31, 2026 and 2025, and as such all awards were anti-dilutive. If the Company was not in a loss position, the calculation of diluted EPS would have included the effect of dilutive common stock equivalents of 188 thousand and 57 thousand, and would have excluded 164 thousand and 396 thousand antidilutive restricted stock awards for the three months ended March 31, 2026 and 2025, respectively.

MEDIFAST INC 10-Q